EnterNext félicite Genfit pour son introduction sur Euronext à Paris


Paris 17 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1],today celebrated the listing of Genfit in compartment B of Euronext’s regulated market in Paris.

Founded in 1999, with facilities in Lille (France) and Cambridge, Massachusetts (USA), Genfit is dedicated to developing therapeutic treatments and diagnostics in fields with major unmet needs, linked primarily to cardiometabolic disorders, with a particular focus on hepatitis complications including NASH[2]. To meet these major public health concerns, Genfit is developing a portfolio of drug candidates and biomarker candidates in its own R&D programs and in programs conducted jointly with large drug companies.

Genfit (ticker symbol: GNFT) was listed through the admission to trading of the 21,257,671 existing shares making up the company’s equity under the direct listing procedure on Euronext’s regulated market in Paris.

Market capitalisation stood at around €464.5 million on the day of listing.

“We are delighted to accompany Genfit as it enters this new stage in its growth,” said Eric Forest, Chairman and CEO of EnterNext, adding “Listing will raise the company’s profile with investors and give it access to greater liquidity to step up deployment of its strategy.”

Jean-François Mouney, Chairman of Genfit’s Management Board, added “Our transfer to compartment B of Euronext Paris is set to boost Genfit’s visibility as we are integrated into a range of benchmark indices, and will also appeal to investors who prefer Euronext’s regulated market.”

[1]Small and medium-sized entreprises
Non-alcoholic steato hepatitis


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.